Decide on other brokers are proposed as different brokers based on administration difficulties and/or adverse result profile.  Zidovudine combined with lamivudine is the alternative NRTI backbone but is associated with additional hematologic toxicity. Lopinavir/ritonavir is an alternate PI agen